Definium Therapeutics (DFTX) director Roger Adsett reports no stock ownership on Form 3
Rhea-AI Filing Summary
Definium Therapeutics director reports no holdings
Definium Therapeutics, Inc. director Roger Adsett filed an initial ownership report stating that he does not beneficially own any Definium Therapeutics securities. The filing is administrative in nature and does not describe any stock purchases, sales, or other transactions.
Positive
- None.
Negative
- None.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What does the Form 3 filing by Roger Adsett at DFTX disclose?
The Form 3 shows that director Roger Adsett currently beneficially owns no securities of Definium Therapeutics, Inc. (DFTX). It is an initial ownership report required for insiders when they first become subject to reporting obligations under U.S. securities laws.
What is Roger Adsett’s role at Definium Therapeutics (DFTX)?
The filing identifies Roger Adsett as a director of Definium Therapeutics, Inc.. As a director, he is considered an insider and must report his holdings and certain changes in ownership on SEC forms such as Form 3, Form 4, and Form 5.
Are there any stock transactions reported for DFTX in this Form 3?
No transactions are reported. The Form 3 simply records that no securities are beneficially owned by director Roger Adsett. It does not include purchases, sales, option grants, or other derivative positions in Definium Therapeutics, Inc. common stock or related instruments.
Why would Definium Therapeutics file a Form 3 with no securities owned?
A Form 3 is required when someone becomes an insider, such as a director. Even if the individual holds no securities, they must file to disclose that fact. Here, Roger Adsett’s Form 3 confirms he currently has no beneficial ownership in DFTX securities.